


WHAT IS CLAIMED IS:

1. A compound of the formula (I):



5

wherein

R¹ is hydrogen, halogen, hydroxy, amino, -CHF₂, -CF₃, or -NHSO₂CH₃;R², R³, and R⁴ are each independently selected from the group consisting of:
hydrogen;

10 halogen;

-(C₁-C₄)alkyl;-CF₃;

amino;

nitro;

15 -(CH₂)_pOR¹⁰;-(CH₂)_nCN;-C(O)NR¹¹R¹²;-C(O)OR¹⁶;-NHC(O)R¹³;20 -O(CH₂)₆Y;-SCH₃;-SO₂R¹⁴;

N-morpholino;

N-piperazine or N-piperazine substituted with (C₁-C₄)alkyl;25 N-pyrrolidine or N-pyrrolidine substituted with -(CH₂)_pOH;


-100-

N-1,1-dioxothiomorpholine;

N-[1,4]-diazepinyl;

phenyl or phenyl substituted with -CF₃, nitro, amino, halogen, hydroxy, (C₁-C₄) alkyl, (C₁-C₄)alkoxy or -NHSO₂CH₃; and

- 5 piperidine or piperidine substituted on the nitrogen with -C(O)(C₁-C₄) alkyl;
or R² and R³ may, together with the phenyl ring to which they are attached, form a naphthaline (benzo-fused ring) of the structure:



R⁵, R⁶ and R⁸ are hydrogen;

- 10 R⁷ and R⁹ are each independently hydrogen or hydroxy;
R¹⁰ is hydrogen, (C₁-C₄)alkyl, -(CF₂)_tCHF₂, -(CH₂)_qNR¹⁷R¹⁸, -(CH₂)_qO(C₁-C₄ alkyl), pyrrolidine, or phenyl;
which pyrrolidine may be optionally substituted on the nitrogen with C₁-C₄ alkyl.
R¹¹ and R¹² are each independently hydrogen or (C₁-C₄)alkyl;
15 R¹³ is (C₁-C₄)alkyl, cyclopropyl or -(CH₂)-OR¹⁹;
R¹⁴ is (C₁-C₄)alkyl, -NR²⁰R²¹, N-pyrrolidine, phenyl, or -CF₃;
R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, and R²¹ are each independently hydrogen or C₁-C₄ alkyl;
m is 0, 1, 2, or 3;
n is 0 or 1;
20 o is 1, 2 or 3;
p is 0, 1 or 2;
q is 1, 2, or 3;
t is 0 or 1;
Y is morpholine, pyrrolidine, or pyrrolidine substituted on the nitrogen by (C₁-C₄)alkyl;
25 and the pharmaceutically acceptable salts thereof.

2. The compound according to **Claim 1**, wherein

R² is hydrogen, C₁-C₄ alkyl, or phenyl;

R³ is hydrogen or hydroxy;

R⁴ is hydrogen, halogen, nitro, cyano, -CF₃, -(CH₂)_pOR¹⁰, or -SO₂R¹⁴;

p is 0;

R¹⁰ is -CHF₂;

R¹⁴ is (C₁-C₄)alkyl; -CF₃; or -NR²⁰R²¹,

5 and the pharmaceutically acceptable salts thereof.

3. The compound according to **Claim 2** wherein R⁴ is nitro;

and the pharmaceutically acceptable salts thereof.

4. The compound according to **Claim 3** wherein R² and R³ are hydrogen.

5. The compound according to **Claim 2** wherein R² is hydrogen; R³ is

10 hydroxy; and R⁴ is hydrogen;

and the pharmaceutically acceptable salts thereof.

6. The compound according to **Claim 1**, which is selected from the group consisting of:

7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-nitrophenyl)-propylamino]-ethyl}-amide,

15 dihydrochloride salt;

7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-cyanophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt;


7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(2-methyl-4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt;

20 (S)-7-Phenyl-isoquinoline-5-sulfonic acid [2-(3-hydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-amide, mesylate salt;

7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-amide isomer 1, dihydrochloride salt; and

25 7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-amide isomer 2, dihydrochloride salt.

7. A compound of the formula:




- 5 wherein R^1 is hydrogen, halogen, hydroxy, amino, $-\text{CHF}_2$ or $-\text{NHSO}_2\text{CH}_3$;
 R^2 , R^3 , and R^4 are each independently:
hydrogen;
halogen;
 $-(\text{C}_1\text{-}\text{C}_4)\text{alkyl}$;
10 $-\text{CF}_3$;
amino;
nitro;
 $-(\text{CH}_2)_p\text{OR}^{10}$;
 $-(\text{CH}_2)_n\text{CN}$;
15 $-\text{C}(\text{O})\text{NR}^{11}\text{R}^{12}$;
 $-\text{C}(\text{O})\text{OR}^{11}$;
 $-\text{NHC}(\text{O})\text{R}^{13}$;
 $-\text{O}(\text{CH}_2)_q\text{Y}$;
 $-\text{SCH}_3$;
20 $-\text{SO}_2\text{R}^{14}$;
N-morpholino;
N-piperazine or N-piperazine substituted with $(\text{C}_1\text{-}\text{C}_4)\text{alkyl}$;
N-pyrrolidine or N-pyrrolidine substituted with $-(\text{CH}_2)_p\text{OH}$;
N-1,1-dioxothiomorpholine;
25 N-[1,4]-diazepinyl;

phenyl or phenyl substituted with -CF₃, nitro, amino, halogen, hydroxy, (C1-C4) alkyl, (C1-C4)alkoxy or -NHSO₂CH₃;

piperidine or piperidine substituted on the nitrogen with -C(O)(C1-C4) alkyl;

or wherein R² and R³ may together with the phenyl ring of formula I form a naphthaline
5 (benzo-fused ring) of the structure:



R⁵, R⁶ and R⁸ are hydrogen;

R⁷ and R⁹ are each independently hydrogen or hydroxy;

R¹⁰ is hydrogen, (C1-C4)alkyl, -(CF₂)_nCHF₂, -(CH₂)_mNR¹¹R¹², -(CH₂)_oO(C1-C4alkyl), or

10 phenyl;

R¹¹ and R¹² are each independently hydrogen or (C1-C4)alkyl;

R¹³ is (C1-C4)alkyl, cyclopropyl or -(CH₂)_oR¹¹;

R¹⁴ is (C1-C4)alkyl, -NR¹¹R¹², N-pyrrolidine, phenyl, or -CF₃;

m is 0, 1, 2, or 3;

15 n is 0 or 1;

o is 1, 2 or 3;

p is 0, 1 or 2;

Y is morpholine, pyrrolidine or pyrrolidine substituted on the nitrogen by (C1-C4)alkyl;
and the pharmaceutically acceptable salts thereof.

20 8. A compound selected from the group consisting of:

7-phenyl-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-difluoromethylphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

25 7-(3-fluorophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-methylsulfonamido)- isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide

7-(3-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide; and

7-(4-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide.

-104-

9. A pharmaceutical composition comprising a compound of any of **Claims 1-7**, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

10. A method for the treatment of susceptible neoplasms comprising
5 administering to a patient in need thereof an effective amount of a compound of any of **Claims 1-7**, or a pharmaceutically acceptable salt thereof.

11. The compound of any of **Claims 1-7**, or a pharmaceutically acceptable salt thereof, for use in therapy.